Clinical trial
Sorafenib, Gemcitabine, and Capecitabine in Treating Patients With Unresectable…
NCT00121251 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00121251 |
|---|---|
| Title | Sorafenib, Gemcitabine, and Capecitabine in Treating Patients With Unresectable and/or Metastatic Kidney Cancer |
| Official title | A Phase I/II Trial of BAY 43-9006 Plus Gemcitabine and Capecitabine in the Treatment of Patients With Advanced Renal Cell Carcinoma |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Recurrent Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v7, Stage IV Renal Cell Cancer AJCC v7 |
| Intervention type | Drug |
| Interventions | Capecitabine, Gemcitabine Hydrochloride, Sorafenib Tosylate |
| Enrollment | 17 |
| Start date | Jun 3, 2005 |
| Primary completion | Mar 14, 2017 |
| Completion | Mar 14, 2017 |
| First posted | Jul 21, 2005 |
| Last update posted | Apr 6, 2021 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: